Alteogen: Block Deal Sale of About 3% of Shares
On 27 March, Alteogen announced that Jeong Hye-shin, former Alteogen Chief Strategy Officer (CSO), sold 1.6 million shares of Alteogen stock (3% of...
501 Views
Alteogen (196170 KS): Modified License Agreement For Major Platform Technology Is A Hard Catalyst
Alteogen modifies license agreement with Merck, granting exclusive global rights for ALT-B4 for pembrolizumab for an upfront payment of $20M and...
499 Views
Alteogen (196170 KS): First Proprietary Product Approval in Korea To Improve Revenue Visibility
Alteogen’s first proprietary recombinant human hyaluronidase liquid product, Tergase (ALT-BB4) is undergoing approval process in Korea and is...
566 Views
Alteogen (196170 KS): Milestone Payments and Pipeline Progress Strengthen Business Growth Prospect
Alteogen is well-position to reap the benefit (milestone payment) of outlicensing of its technology and is expected to turn profitable on triple...
340 Views
2023 in Rear Mirror View: Top Performers From My Global Healthcare Coverage Universe
Despite ongoing recovery and fading effect of the COVID-19, healthcare companies had varying performances in 2023. From my coverage, the top...
575 Views